Patents Assigned to Allergan, Inc.
  • Methods of intracellular conversion of single-chain proteins into their di-chain form
    Patent number: 9938514
    Abstract: The present specification discloses expression constructs comprising single-chain proteins comprising a di-chain loop region comprising an exogenous protease cleavage site and a protease that can cleave the exogenous protease cleavage site located within the di-chain loop, cell compositions comprising such expression construct, and intracellular methods of converting the single-chain protein into its di-chain form.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: April 10, 2018
    Assignee: Allergan, Inc.
    Inventors: Sanjiv Ghanshani, Linh Q. Le, Yi Liu, Lance E. Steward
  • Non-irritating testosterone emulsions
    Patent number: 9937188
    Abstract: Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: April 10, 2018
    Assignee: Allergan, Inc.
    Inventors: John T. Trogden, Adnan K. Salameh, Chetan P. Pujara, Anuradha V. Gore, Jaya Giyanani, Andrea S. Kim, Mayssa Attar, Ronald Bradford, Rhett M. Schiffman
  • Nucleic acids encoding complement component C5 antibodies
    Patent number: 9932395
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: April 3, 2018
    Assignees: Allergan, Inc., Xencor, Inc.
    Inventors: Peter C. Baciu, Yanbin Liang, Jason Guu, Matthew Bernett, Umesh Muchhal, John Desjarlais
  • Phenylcarbamate derivatives as formyl peptide receptor modulators
    Patent number: 9926264
    Abstract: The present invention relates to N-phenyl carbamate derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide 2 receptor.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: March 27, 2018
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, Michael E. Garst
  • EP4 agonists as therapeutic compounds
    Patent number: 9926262
    Abstract: Described herein are compounds that are EP4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EP4 receptors.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: March 27, 2018
    Assignee: ALLERGAN, INC.
    Inventors: David W. Old, Christopher D. Hein
  • Soft filled prosthesis shell with discrete fixation surfaces
    Patent number: 9918829
    Abstract: A soft prosthetic implant shell, such as a silicone breast implant shell, that has discrete fixation surfaces thereon for tissue adhesion. The fixation surfaces may be provided on the posterior face of the shell, as well as either on the periphery or at discrete areas on the anterior face. Band-shaped fixation surfaces may be provided on the anterior face of the shell to generally match the angle of pectoralis major or pectoralis minor muscle groups. The fixation surfaces may be roughened areas of the shell, or may be separate elements adhered to the shell.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: March 20, 2018
    Assignee: Allergan, Inc.
    Inventors: Dennis Van Epps, Thomas E. Powell
  • 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators
    Patent number: 9920013
    Abstract: The present invention relates to 1-(2,5-dioxoimidazolidin-1-yl)-3-substituted urea compounds, processes for preparing them, pharmaceutical compositions containing them, their use as pharmaceuticals as modulators of the FPR2 receptor, and to methods of treating inflammatory diseases or conditions in a subject in need thereof by administering the compound(s) or pharmaceutical composition to the subject.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: March 20, 2018
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Vidyasagar Vuligonda, Thong Huy Vu, Michael E. Garst
  • Autoclavable suspensions of cyclosporin A Form 2
    Patent number: 9919028
    Abstract: Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: March 20, 2018
    Assignee: Allergan, Inc.
    Inventors: Wendy M. Blanda, Hongwen Ma Rivers, David A. Marsh, Michelle Luu
  • Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
    Patent number: 9914755
    Abstract: The present invention relates to cyclosporin analogs that are potent inhibitors of cyclophilin D and have low immunosuppressive activity; processes for preparing them; pharmaceutical compositions containing them; and methods for using these analogs and compositions containing them for the treatment of medical conditions, including but not limited to ischemic conditions, such as ischemia-reperfusion (I/R) injury, including myocardial FR injury, cerebral I/R injury, and ocular or retinal I/R injury.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: March 13, 2018
    Assignee: Allergan, Inc.
    Inventors: Simon N. Pettit, Andrew D. Jones, Catherine Simone V. Frydrych, Alex J. Thomas, Michael E. Garst
  • Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
    Patent number: 9907826
    Abstract: Provided herein are low salt ophthalmic pharmaceutical composition and methods of use thereof, for example, in the treatment of dry eye syndrome.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: March 6, 2018
    Assignee: ALLERGAN, INC.
    Inventors: Peter A. Simmons, Joseph G. Vehige
  • Method for treating premature ejaculation with a botulinum neurotoxin
    Patent number: 9907841
    Abstract: Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such as botulinum neurotoxin, to the patient, are provided.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: March 6, 2018
    Assignee: Allergan, Inc.
    Inventors: Ivan Aguilar, Gustavo M. Gaxiola, Gilberto P. Paz
  • Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
    Patent number: 9902710
    Abstract: The invention relates to compounds of the formula or a pharmaceutically acceptable salt thereof, wherein R?, R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: February 27, 2018
    Assignees: EXONHIT THERAPEUTICS, SA, ALLERGAN, INC.
    Inventors: Bertrand Leblond, Thierry Taverne, Cedric Chauvignac, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Desire, Matthew P. Pando, John E. Donello, Rong Yang
  • Compositions containing aromatic aldehydes and their use in treatments
    Patent number: 9895361
    Abstract: Disclosed are pharmaceutical and cosmetic compositions containing aromatic aldehyde compounds. Some of the disclosed compositions are useful as topical therapeutics for treating inflammatory dermatologic conditions. Some of the compositions are useful in transdermal and other systemic dose forms for treating other inflammatory conditions in mammals.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: February 20, 2018
    Assignee: Allergan, Inc.
    Inventors: Charles R. Engles, Bryan Fuller, Brian Keith Pilcher
  • Prostamide-containing intraocular implant
    Patent number: 9889142
    Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: February 13, 2018
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Jie Shen, Michael R. Robinson, David F. Woodward, Robert M. Burk, Hui Liu, Jinping Wan, Chandrasekar Durairaj, Gyorgy F. Ambrus, Ke Wu, Danny T. Dinh
  • Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
    Patent number: 9889088
    Abstract: The present invention provides a method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising 4-bromo-5-(2-imidazolin-2-ylamino)benzimidazole, or a salt thereof to the affected eye of a patient, as a single dose, wherein the affected eye has an intraocular pressure less than the baseline intraocular pressure for at least eight (8) hours.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: February 13, 2018
    Assignee: Allergan, Inc.
    Inventors: Mohammed I. Dibas, Daniel W. Gil, John E. Donello
  • Prostamides for the treatment of glaucoma and related diseases
    Patent number: 9890118
    Abstract: Disclosed herein are compositions comprising an amide related to a prostaglandin and a biogenic amine. Other aspects relate to certain chemical compounds, pharmaceutical compositions, and methods of treating glaucoma.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: February 13, 2018
    Assignee: ALLERGAN, INC.
    Inventors: David F. Woodward, Robert M. Burk
  • Carbamoyl hydrazine derivatives as formyl peptide modulators
    Patent number: 9868700
    Abstract: The present invention relates to carbamoyl hydrazine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the FPR receptor.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: January 16, 2018
    Assignee: Allergan, Inc.
    Inventors: Vidyasagar Vuligonda, Thong Vu, Veena Viswanath, John E. Donello, Richard L. Beard
  • Adipose tissue combinations, devices, and uses thereof
    Patent number: 9867939
    Abstract: Described are devices, systems, and methods for processing adipose tissue for reintroduction into a body. In some embodiments, adipose tissue is mixed with an additive prior to reintroduction.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: January 16, 2018
    Assignee: Allergan, Inc.
    Inventors: Justin Schwab, Mike Augarten, Darin Messina, Jason Metzner, Ethan Franklin
  • Pyridyl benzothiophenes as kinase inhibitors
    Patent number: 9868726
    Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: January 16, 2018
    Assignee: ALLERGAN, INC.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
    Patent number: 9861576
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: January 9, 2018
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, Alazar N. Ghebremeskel, Michael R. Robinson